Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Zerify Inc (ZRFY) Message Board

Link for tomorrow's hearing Tuesday 2:30 pm est

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 82686
(Total Views: 474)
Posted On: 06/10/2019 12:23:34 PM
Avatar
Posted By: gimli
Link for tomorrow's hearing Tuesday 2:30 pm est

https://www.judiciary.senate.gov/meetings/the...a-part-iii

This will be the third of three hearings held by the Senate IP Subcommittee to explore both current issues in U.S. patent eligibility as well as the proposed legislative fix to Section 101 of U.S. patent law meant to address those issues. There will be three witness panels to testify during this hearing. The first panel will include Manny Schecter, Chief Patent Counsel, IBM; Laurie Self, Senior Vice President and Counsel, Government Affairs, Qualcomm; Byron Holz, Senior Intellectual Property Rights Licensing Counsel, Nokia; Kim Chotkowski, Vice President, Head of Licensing Strategy and Operations, InterDigital; and Sean Reilly, Senior Vice President and Associate General Counsel, The Clearing House Payments Company. The second panel will include Laurie Hill, Vice President, Intellectual Property, Genentech; Sean George, CEO, Invitae; Gonzalo Merino, Vice President and Chief Intellectual Property Counsel, Regeneron Pharmaceuticals; Peter O’Neill, Executive Director, Cleveland Clinic Innovations; and Dr. David Spetzler, President and Chief Scientific Officer, Caris Life Sciences. The third panel will include Michael Blankstein, Senior Vice President and Deputy General Counsel, Patents and Licensing, Scientific Games; Corey Salsberg, Vice President, Global Head IP Affairs, Novartis; Nicolas Dupont, CEO and Executive Chairman, Cyborg Inc.; Robert DeBerardine, Chief Intellectual Property Counsel, Johnson & Johnson; and John Vandenberg, Partner, Klarquist Sparkman, LLP. More information on the panel roster for this hearing can be found here.


(2)
(0)




Zerify Inc (ZRFY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us